Solicitation
NAICS 541714
Treating Hereditary Rare Diseases With In Vivo Precision Genetic Medicines (THRIVE)
Amendment 1: Added the Frequently Asked Questions (FAQ) to the list of attachments. The Advanced Research Projects Agency for Health (ARPA-H) Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) program envisions a future where patients can opt for one-time therapeutic interventions designed to slow, reverse, or cure disease, harnessing revolutionary technologies and a rapidly evolving understanding of the genetic underpinnings of the biological processes that lead to disease. Interested parties are invited to review the attached THRIVE Innovative Solutions Opening (ISO) ARPA-H -SOL-25-122. For detailed information regarding Proposers' Day review Special Notice (SN) ARPA-H-SN-25-131. Solution summaries are due October 31, 2025, 11:59 PM ET. For more information about THRIVE, please visit:https://arpa-h.gov/explore-funding/programs/thrive
Notice ID: 2bb6a4d38f9c42889150b8268506111c ·
View on SAM.gov ↗
Explore more federal-contracting data
Browse opportunities by NAICS code · set-aside category · state & jurisdiction · buying agency
Win more federal contracts
BidChamp gives small businesses AI-powered bid writing, document analysis, and recompete forecasting - for free during your trial.
Sign up free - 14-day trial, no card required